CRISPR-Cas9 vs Base Editing
CRISPR-Cas9 and base editing represent two generations of gene editing technology. CRISPR cuts DNA like molecular scissors and relies on cellular repair, while base editing chemically converts individual bases without breaking the double helix. With Casgevy (CRISPR) FDA-approved since December 2023 and Beam Therapeutics achieving the first-ever clinical correction of a disease-causing point mutation via base editing in March 2025, both technologies are now clinically validated but serve different therapeutic needs.
Last updated: March 29, 2026
CRISPR-Cas9
The foundational gene editing tool. Uses a guide RNA to direct the Cas9 protein to cut both strands of DNA at a specific location, then relies on the cell's repair machinery (NHEJ or HDR) to make changes.
Base Editing
A refined approach that uses a deaminase enzyme fused to a modified Cas9 (nickase) to chemically convert one DNA base into another without cutting the double helix. Like using a pencil eraser and rewriting instead of scissors.
Key Specifications
| Feature | CRISPR-Cas9 | Base Editing |
|---|---|---|
| Mechanism | Double-strand DNA break + cellular repair | Chemical base conversion via deaminase (no DSB) |
| Precision | Gene-level (±several bases, indel mix) | Single-base pair |
| Edit types | Insertions, deletions, replacements, gene knockout | C·G→T·A (CBE) and A·T→G·C (ABE) |
| Off-target risk | Moderate (reduced with HiFi Cas9, eSpCas9) | Low (indels), moderate (RNA off-targets) |
| FDA-approved therapies | 1 — Casgevy (SCD & TDT, Dec 2023) | 0 — but BLA submission targeted 2026 (BEAM-101) |
| Active clinical trials | ~100+ (ClinicalTrials.gov, 2026) | ~8-10 (Beam, Verve/Lilly, academic) |
| Key companies | Vertex/CRISPR Therapeutics, Intellia, Editas, Caribou | Beam Therapeutics, Verve/Eli Lilly |
| In vivo delivery | LNP (liver, Phase 3), AAV, VLPs (preclinical) | LNP (liver-directed, Phase 1b) |
| Discovery year | 2012 (Doudna & Charpentier) | 2016 (David Liu, Broad Institute) |
| 2025 commercial revenue | Casgevy: $116M (64 patients infused) | — |
| 2025 milestone | — | First clinical correction of disease mutation (BEAM-302, AATD) |
CRISPR-Cas9
Advantages
- Can make any type of edit — insertions, deletions, and replacements
- First CRISPR therapy (Casgevy) FDA-approved Dec 2023, with $116M revenue and ~165 patients treated in 2025
- ~100+ active clinical trials on ClinicalTrials.gov as of early 2026
- Multiplexing: can target multiple genes simultaneously (used in allogeneic CAR-T like zugo-cel)
- In vivo CRISPR via LNP delivery proven in humans (Intellia's NTLA-2001: 93% TTR knockdown sustained 3+ years)
- Expanding beyond liver: new Cas variants (CasX, Cas12a, CasMINI) enable smaller payloads
Limitations
- Creates double-strand breaks (DSBs) which can cause unwanted indels and chromosomal rearrangements
- Off-target edits at similar DNA sequences remain a concern despite high-fidelity variants
- Cell stress from DSBs can trigger p53-mediated apoptosis, selecting for p53-deficient cells
- Repair outcomes via NHEJ are somewhat unpredictable — creates a mix of indels
- PAM sequence requirement limits targetable sites (partially addressed by PAM-relaxed variants like SpRY)
- Complex IP landscape with ongoing Broad Institute vs UC Berkeley patent disputes
Base Editing
Advantages
- No double-strand breaks — cleaner, more predictable edits with minimal indels
- Single-base precision for point mutations — can correct ~60% of known disease-causing mutations
- First clinical genetic correction achieved: Beam's BEAM-302 corrected AATD mutation in patients (March 2025)
- BEAM-101 for SCD: 30 patients dosed, FDA RMAT designation (Aug 2025), BLA submission targeted year-end 2026
- Lower off-target indel rates compared to nuclease CRISPR
- Verve's VERVE-102 showed 53-69% LDL-C reduction via single IV dose (in vivo base editing)
Limitations
- Limited to specific base conversions: C→T, G→A (CBE) and A→G, T→C (ABE) — 4 of 12 possible transitions
- Cannot make insertions or deletions — only point mutations
- Bystander editing of nearby bases within the editing window (~4-8 nt)
- RNA off-target deamination possible (addressed by engineered variants like ABE8e-V106W)
- Larger protein size (~5.2 kb) makes AAV delivery challenging — mostly LNP-delivered
- Verve's VERVE-101 trial saw safety signals (grade 3 ALT elevation, thrombocytopenia, potentially related MI)
The Verdict
As of 2026, CRISPR-Cas9 is the clinically proven leader with an FDA-approved therapy generating $116M in revenue and 100+ active trials. Base editing is catching up fast — Beam's historic first clinical correction of a disease-causing mutation (BEAM-302 for AATD, March 2025) validated the technology in humans, and BLA submission for BEAM-101 is targeted for year-end 2026. Choose CRISPR-Cas9 when you need gene knockout, large edits, or insertions. Choose base editing when correcting a single-letter point mutation with maximum precision and minimal collateral DNA damage. For the ~60% of genetic diseases caused by point mutations, base editing may ultimately prove the more elegant and safer approach.